PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
18.13%
Revenue growth of 18.13% vs. zero growth in Drug Manufacturers - Specialty & Generic. Walter Schloss might still want to see if it can translate into profits.
126.49%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.46%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
7.01%
EBIT growth below 50% of Drug Manufacturers - Specialty & Generic median of 19.56%. Jim Chanos would suspect fundamental operating challenges.
7.01%
Operating income growth below 50% of Drug Manufacturers - Specialty & Generic median of 21.66%. Jim Chanos would suspect structural cost disadvantages.
-223.94%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 12.20%. Seth Klarman would investigate factors dragging net income down.
-151.50%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is 16.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-151.50%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is 15.38%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.66%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
0.66%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-1622.35%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is -10.92%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-40695.39%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is -5.95%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
591.73%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.09%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
590.91%
3Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.99%. Joel Greenblatt might see a short-term competitive advantage at play.
-9912.68%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-1199.97%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-255.95%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-2334.26%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 14.65%. Seth Klarman might see a fundamental problem if peers maintain growth.
-938.00%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 0.11%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-207.50%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is -1.96%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
9571.99%
Equity/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 55.18% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
979.62%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 32.61%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
63.77%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 15.20%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.86%
AR growth of 10.86% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
-1.92%
Decreasing inventory while Drug Manufacturers - Specialty & Generic is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-0.65%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-2.43%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is -0.95%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-6.92%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
119.27%
We slightly increase R&D while Drug Manufacturers - Specialty & Generic is cutting. Peter Lynch sees a chance to grab market share with new offerings if ROI is managed well.
34.23%
Our SG&A slightly up while Drug Manufacturers - Specialty & Generic is cutting. Peter Lynch wonders if we overspend or if the median underinvests in marketing.